| Name | Title | Contact Details |
|---|
Caregiver, Inc. is one of the largest providers of support services to people with intellectual and developmental disabilities and traumatic brain injury in the United States. We currently operate in Texas and Tennessee under multiple local brands, including: Daybreak Community Services Unified Care Group Southern Concepts River Gardens St. Giles Omni Support Services/Caregiver of Tennessee Our Mission is "Enabling people with intellectual and developmental disabilities to lead their unique lives with dignity, independence and inclusion." We believe in recruiting, training and developing the best people to support the individuals we serve; enabling them with tools and technology to provide individualized supports. We care deeply about the people we serve and strive to serve their unique goals and dreams. We work with integrity, accountability, transparency, and compassion in everything we do, because we understand those we serve have a choice in providers. We offer residential, intermediate care facility, supported living/foster care, day support, community integration and employment support services in both Texas and Tennessee. In addition, Caregiver has a newly developed Behavioral Support Services team supporting those we serve in Texas.
Aurora Spine Corporation focuses on the development and distribution of spinal implant products for relieving back pain, and preserving spinal bone structure and anatomy in the United States. The company intends to provide interspinous process lumbar fusion devices for patients suffering from degenerative disc disease whose pain has not been eliminated by non-surgical treatment methods; polyether ether ketone interbody cages for use in spinal fusion procedures; and cervical and lumbar devices. It also plans to develop installation tools for surgeons. The company was incorporated in 2013 and is headquartered in Toronto, Canada.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. We are proud of addressing some of the most challenging healthcare issues. Our vision – value through innovation – has always characterized our collaborative work, and is for us simultaneously a fundamental requirement and a driving force. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees.
Perimed is a North Royalton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.